PharmaDrug Inc CEO Daniel Cohen tells Proactive that the Terasaki Institute for Biomedical Innovation (TIBI) will begin in vitro characterization studies on PharmaDrug's short-list of DMT molecules, which will support IND-enabling studies for the FDA to review. Cohen detailed the steps it will take with TIBI, under a research agreement, to develop a novel ocular drug delivery platform that aims to deliver psychedelic and tryptamine-based pharmaceuticals, related to DMT for eye diseases.
PharmaDrug details upcoming program with Terasaki using DMT formulation to cure eye diseases
